Sinovac Biotech Ltd (SVA) — Capital Reinvestment Ratio

Latest as of December 2023: 0.36x

Sinovac Biotech Ltd (SVA) has a Capital Reinvestment Ratio of 0.36x as of December 2023, meaning it reinvests 0% of its operating cash flow ($146.01 Million) in capital expenditures ($52.75 Million). Check Sinovac Biotech Ltd tangible equity quality to evaluate the tangible quality of the company's equity base.

Capital Reinvestment Ratio

0.36x
Capex / Operating Cash Flow

Operating Cash Flow

$146.01 Million
USD

Capital Expenditures

$52.75 Million
USD

Data as of

Dec 2023
Most recent filing

Sinovac Biotech Ltd Capital Reinvestment Ratio (2007–2023)

This chart tracks Sinovac Biotech Ltd's Capital Reinvestment Ratio across 12 annual periods. For the full cash flow conversion analysis, see Sinovac Biotech Ltd (SVA) cash conversion ratio.

Annual Capital Reinvestment Ratio for Sinovac Biotech Ltd (2007–2023)

Year-by-year Capital Reinvestment Ratio for Sinovac Biotech Ltd from 2007 to 2023. See Sinovac Biotech Ltd free cash flow ratio to measure how efficiently the company converts operating cash flow to free cash.

Year Reinvestment Ratio Operating CF (USD) Capital Expenditures YoY Change
2023 1.37x $106.02 Million $145.69 Million ▲ +2830.3%
2021 0.05x $15.35 Billion $719.98 Million ▼ -82.4%
2020 0.27x $479.31 Million $127.65 Million ▼ -2.1%
2019 0.27x $39.07 Million $10.63 Million ▼ -61.5%
2018 0.71x $7.94 Million $5.61 Million ▲ +254.4%
2017 0.20x $59.76 Million $11.91 Million ▼ -84.2%
2015 1.26x $4.21 Million $5.30 Million ▲ +36.7%
2013 0.92x $5.58 Million $5.13 Million ▼ -17.0%
2011 1.11x $13.94 Million $15.46 Million ▲ +1142.9%
2009 0.09x $48.41 Million $4.32 Million ▼ -76.4%
2008 0.38x $10.50 Million $3.98 Million ▼ -33.8%
2007 0.57x $4.32 Million $2.47 Million
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow